Multiple facets of junD gene expression are atypical among AP-1 family members

Oncogene

Volumn 27, Issue 35, 2008, Pages 4757-4767

  Hernandez, J M ^a   Floyd, D H ^b   Weilbaecher, K N ^b   Green, P L ^a,c   Boris Lawrie, K ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

AP 1; Cancer; Heart failure; HTLV 1; JunD; RNA helicase A and post transcriptional control element

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; COLLAGENASE 3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; FERRITIN; HETERODIMER; INTERLEUKIN 5; INTERLEUKIN 6; LEUCINE ZIPPER PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NUCLEAR RECEPTOR NUR77; OSTEOCALCIN; PROTEIN BCL 6; PROTEIN P19; RNA HELICASE; RNA HELICASE A; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUND;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; AMINO TERMINAL SEQUENCE; CELL CYCLE REGULATION; CELL GROWTH; DNA BINDING; ENZYME ACTIVITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; MULTIPLE ENDOCRINE NEOPLASIA; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; REVIEW; T CELL LEUKEMIA; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTOR AP-1;

HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 49649113832     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.120     Document Type: Review

References (100)

1. Abdelhaleem M. (2003). The actinomycin D-induced apoptosis in BCR-ABL-positive K562 cells is associated with cytoplasmic translocation and cleavage of RNA helicase A. Anticancer Res 23: 485-490.
2. Adler V, Unlap T, Kraft AS. (1994). A peptide encoding the c-Jun delta domain inhibits the activity of a c-jun amino-terminal protein kinase. J Biol Chem 269: 11186-11191.
3. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY et al. (1999). Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96: 143-152.
4. Agarwal SK, Novotny EA, Crabtree JS, Weitzman JB, Yaniv Jr M, Burns AL et al. (2003). Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci USA 100: 10770-10775.
5. Akhouayri O, St Arnaud R. (2007). Differential mechanisms of transcriptional regulation of the mouse osteocalcin gene by Jun family members. Calcif Tissue Int 80: 123-131.
6. Alcivar AA, Hake LE, Kwon YK, Hecht NB. (1991). junD mRNA expression differs from c-jun and junB mRNA expression during male germinal cell differentiation. Mol Reprod Dev 30: 187-193.
7. Arguni E, Arima M, Tsuruoka N, Sakamoto A, Hatano M, Tokuhisa T. (2006). JunD/AP-1 and STAT3 are the major enhancer molecules for high Bcl6 expression in germinal center B cells. Int Immunol 18: 1079-1089.
8. Arnold J, Yamamoto B, Li M, Phipps AJ, Younis I, Lairmore MD et al. (2006). Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of HTLV-1. Blood 107: 3976-3982.
9. Baird SD, Turcotte M, Korneluk RG, Holcik M. (2006). Searching for IRES. RNA 12: 1755-1785.
10. Basbous J, Arpin C, Gaudray G, Piechaczyk M, Devaux C, Mesnard JM. (2003). The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. J Biol Chem 278: 43620-43627.
11. Berger I, Shaul Y. (1991). Structure and function of human jun-D. Oncogene 6: 561-566.
12. Berger I, Shaul Y. (1994). The human junD gene is positively and selectively autoregulated. DNA Cell Biol 13: 249-255.
13. Bolinger C, Yilmaz A, Hartman TR, Kovacic MB, Fernandez S, Ye J et al. (2007). RNA helicase A interacts with divergent lymphotropic retroviruses and promotes translation of human T-cell leukemia virus type 1. Nucleic Acids Res 35: 2629-2642.
14. Braddock M, Muckenthaler M, White MR, Thorburn AM, Sommerville J, Kingsman AJ et al. (1994). Intron-less RNA injected into the nucleus of Xenopus oocytes accesses a regulated translation control pathway. Nucleic Acids Res 22: 5255-5264.
15. Butsch M, Hull S, Wang Y, Roberts TM, Boris-Lawrie K. (1999). The 5′ RNA terminus of spleen necrosis virus contains a novel posttranscriptional control element that facilitates human immunodeficiency virus Rev/RRE-independent Gag production. J Virol 73: 4847-4855.
16. Cavanagh MH, Landry S, Audet B, Arpin-Andre C, Hivin P, Pare ME et al. (2006). HTLV-I antisense transcripts initiating in the 3′LTR are alternatively spliced and polyadenylated. Retrovirology 3: 15.
17. De Groot RP, Karperien M, Pals C, Kruijer W. (1991). Characterization of the mouse junD promoter - high basal level activity due to an octamer motif. EMBO J 10: 2523-2532.
18. Dreijerink KM, Hoppener JW, Timmers HM, Lips CJ. (2006). Mechanisms of disease: multiple endocrine neoplasia type 1 - relation to chromatin modifications and transcription regulation. Nat Clin Pract Endocrinol Metab 2: 562-570.
19. Eferl R, Wagner EF. (2003). AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868.
20. Finkel T. (2006). Intracellular redox regulation by the family of small GTPases. Antioxid Redox Signal 8: 1857-1863.
21. Fries F, Nazarenko I, Hess J, Claas A, Angel P, Zoller M. (2007). CEBPbeta, JunD and c-Jun contribute to the transcriptional activation of the metastasis-associated C4.4A gene. Int J Cancer 120: 2135-2147.
22. Fuchs SY, Xie B, Adler V, Fried VA, Davis RJ, Ronai Z. (1997). c-Jun NH2-terminal kinases target the ubiquitination of their associated transcription factors. J Biol Chem 272: 32163-32168.
23. Gallo A, Cuozzo C, Esposito I, Maggiolini M, Bonofiglio D, Vivacqua A et al. (2002). Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation. Oncogene 21: 6434-6445.
24. Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D et al. (2004). JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118: 781-794.
25. Gobl AE, Berg M, Lopez-Egido JR, Oberg K, Skogseid B, Westin G. (1999). Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism. Biochim Biophys Acta 1447: 51-56.
26. Gudikote JP, Imam JS, Garcia RF, Wilkinson MF. (2005). RNA splicing promotes translation and RNA surveillance. Nat Struct Mol Biol 12: 801-809.
27. Gunthert AR, Grundker C, Hollmann K, Emons G. (2002). Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells. Biochem Biophys Res Commun 294: 11-15.
28. Hai T, Curran T. (1991). Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci USA 88: 3720-3724.
29. Harper JW, Elledge SJ. (1999). Skipping into the E2F1-destruction pathway. Nat Cell Biol 1: E5-E7.
30. Hartman TR, Qian S, Bolinger C, Fernandez S, Schoenberg DR, Boris-Lawrie K. (2006). RNA helicase A is necessary for translation of selected messenger RNAs. Nat Struct Mol Biol 13: 509-516.
31. Hendy GN, Kaji H, Sowa H, Lebrun JJ, Canaff L. (2005). Menin and TGF-beta superfamily member signaling via the Smad pathway in pituitary, parathyroid and osteoblast. Horm Metab Res 37: 375-379.
32. Herschman HR. (1991). Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem 60: 281-319.
33. Hess J, Angel P, Schorpp-Kistner M. (2004). AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117: 5965-5973.
34. Hilfiker-Kleiner D, Hilfiker A, Kaminski K, Schaefer A, Park JK, Michel K et al. (2005). Lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and angiogenesis in the heart. Circulation 112: 1470-1477.
35. Hirai SI, Ryseck RP, Mechta F, Bravo R, Yaniv M. (1989). Characterization of junD: a newmember of the jun proto-oncogene family. EMBO J 8: 1433-1439.
36. Hivin P, Arpin-Andre C, Clerc I, Barbeau B, Mesnard JM. (2006). A modified version of a Fos-associated cluster in HBZ affects Jun transcriptional potency. Nucleic Acids Res 34: 2761-2772.
37. Ijiri K, Zerbini LF, Peng H, Correa RG, Lu B, Walsh N et al. (2005). A novel role for GADD45beta as a mediator of MMP-13 gene expression during chondrocyte terminal differentiation. J Biol Chem 280: 38544-38555.
38. Jochum W, Passegue E, Wagner EF. (2001). AP-1 in mouse development and tumorigenesis. Oncogene 20: 2401-2412.
39. Kallunki T, Deng T, Hibi M, Karin M. (1996). c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 87: 929-939.
40. Kameda T, Watanabe H, Iba H. (1997). C-Jun and JunD suppress maturation of chondrocytes. Cell Growth Differ 8: 495-503.
41. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. (1998). Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95: 8292-8297.
42. Kim H, Lee JE, Cho EJ, Liu JO, Youn HD. (2003). Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Res 63: 6135-6139.
43. Kim H, Lee JE, Kim BY, Cho EJ, Kim ST, Youn HD. (2005). Menin represses JunD transcriptional activity in protein kinase C theta-mediated Nur77 expression. Exp Mol Med 37: 466-475.
44. Kim J, Cantwell CA, Johnson PF, Pfarr CM, Williams SC. (2002). Transcriptional activity of CCAAT/enhancer-binding proteins is controlled by a conserved inhibitory domain that is a target for sumoylation. J Biol Chem 277: 38037-38044.
45. Kozak M. (1984a). Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res 12: 857-872.
46. Kozak M. (1984b). Selection of initiation sites by eucaryotic ribosomes: effect of inserting AUG triplets upstream from the coding sequence for preproinsulin. Nucleic Acids Res 12: 3873-3893.
47. Kuhlmann AS, Villaudy J, Gazzolo L, Castellazzi M, Mesnard JM, Duc DM. (2007). HTLV-1 HBZ cooperates with JunD to enhance transcription of the human telomerase reverse transcriptase gene (hTERT). Retrovirology 4: 92.
48. Larocca D, Chao LA, Seto MH, Brunck TK. (1989). Human T-cell leukemia virus minus strand transcription in infected T-cells. Biochem Biophys Res Commun 163: 1006-1013.
49. Li L, Liu L, Rao JN, Esmaili A, Strauch ED, Bass BL et al. (2002a). JunD stabilization results in inhibition of normal intestinal epithelial cell growth through P21 after polyamine depletion. Gastroenterology 123: 764-779.
50. Li M, Green PL. (2007). Detection and quantitation of HTLV-1 and HTLV-2 mRNA species by real-time RT-PCR. J Virol Methods 142: 159-168.
51. Li T, Dai W, Lu L. (2002b). Ultraviolet-induced junD activation and apoptosis in myeloblastic leukemia ML-1 cells. J Biol Chem 277: 32668-32676.
52. Li Y, Jenkins CW, Nichols MA, Xiong Y. (1994). Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9: 2261-2268.
53. Matsumoto J, Ohshima T, Isono O, Shimotohno K. (2005). HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein. Oncogene 24: 1001-1010.
54. Matsumoto K, Wassarman KM, Wolffe AP. (1998). Nuclear history of a pre-mRNA determines the translational activity of cytoplasmic mRNA. EMBO J 17: 2107-2121.
55. Matsuoka M, Jeang KT. (2007). Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 7: 270-280.
56. McCabe LR, Banerjee C, Kundu R, Harrison RJ, Dobner PR, Stein JL et al. (1996). Developmental expression and activities of specific fos and jun proteins are functionally related to osteoblast maturation: role of Fra-2 and Jun D during differentiation. Endocrinology 137: 4398-4408.
57. Mechta-Grigoriou F, Gerald D, Yaniv M. (2001). The mammalian Jun proteins: redundancy and specificity. Oncogene 20: 2378-2389.
58. Mehic D, Bakiri L, Ghannadan M, Wagner EF, Tschachler E. (2005). Fos and jun proteins are specifically expressed during differentiation of human keratinocytes. J Invest Dermatol 124: 212-220.
59. Meixner A, Karreth F, Kenner L, Wagner EF. (2004). JunD regulates lymphocyte proliferation and T helper cell cytokine expression. EMBO J 23: 1325-1335.
60. Merrick WC, Hershey JWB. (1996). . In: Hershey JWB, Mathews DH and Sonenberg N (eds) Translational Control. Cold Spring Harbor Laboratory Press: Plainview, pp 31-69.
61. Milde-Langosch K. (2005). The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 41: 2449-2461.
62. Morgan IM, Asano M, Havarstein LS, Ishikawa H, Hiiragi T, Ito Y et al. (1993). Amino acid substitutions modulate the effect of Jun on transformation, transcriptional activation and DNA replication. Oncogene 8: 1135-1140.
63. Musti AM, Treier M, Peverali FA, Bohmann D. (1996). Differential regulation of c-Jun and JunD by ubiquitin-dependent protein degradation. Biol Chem 377: 619-624.
64. Myohanen S, Baylin SB. (2001). Sequence-specific DNA binding activity of RNA helicase A to the p16INK4a promoter. J Biol Chem 276: 1634-1642.
65. Naito J, Kaji H, Sowa H, Hendy GN, Sugimoto T, Chihara K. (2005). Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD. J Biol Chem 280: 4785-4791.
66. Neyns B, Katesuwanasing, Vermeij J, Bourgain C, Vandamme B, Amfo K et al. (1996). Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium. Oncogene 12: 1247-1257.
67. Nott A, Le Hir H, Moore MJ. (2004). Splicing enhances translation in mammalian cells: an additional function of the exon junction complex. Genes Dev 18: 210-222.
68. Okazaki S, Ito T, Ui M, Watanabe T, Yoshimatsu K, Iba H. (1998). Two proteins translated by alternative usage of initiation codons in mRNA encoding a JunD transcriptional regulator. Biochem Biophys Res Commun 250: 347-353.
69. Persengiev SP, Green MR. (2003). The role of ATF/CREB family members in cell growth, survival and apoptosis. Apoptosis 8: 225-228.
70. Pfarr CM, Mechta F, Spyrou G, Lallemand D, Carillo S, Yaniv M. (1994). Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras. Cell 76: 747-760.
71. Pollack PS, Pasquarello LM, Budjak R, Fernandez E, Soprano KJ, Redfern BG et al. (1997). Differential expression of c-jun and junD in end-stage human cardiomyopathy. J Cell Biochem 65: 245-253.
72. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L et al. (1998). The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2′s inhibition of p53. Cell 92: 713-723.
73. Punga T, Bengoechea-Alonso MT, Ericsson J. (2006). Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding. J Biol Chem 281: 25278-25286.
74. Robb GB, Rana TM. (2007). RNA helicase A interacts with RISC in human cells and functions in RISC loading. Mol Cell 26: 523-537.
75. Roberts TM, Boris-Lawrie K. (2000). The 5′ RNA terminus of spleen necrosis virus stimulates translation of nonviral mRNA. J Virol 74: 8111-8118.
76. Roberts TM, Boris-Lawrie K. (2003). Primary sequence and secondary structure motifs in spleen necrosis virus RU5 confer translational utilization of unspliced human immunodeficiency virus type 1 reporter RNA. J Virol 77: 11973-11984.
77. Schwenger GT, Kok CC, Arthaningtyas E, Thomas MA, Sanderson CJ, Mordvinov VA. (2002). Specific activation of human interleukin-5 depends on de novo synthesis of an AP-1 complex. J Biol Chem 277: 47022-47027.
78. Short JD, Pfarr CM. (2002). Translational regulation of the JunD messenger RNA. J Biol Chem 277: 32697-32705.
79. Srivastava S, Weitzmann MN, Cenci S, Ross FP, Adler S, Pacifici R. (1999). Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J Clin Invest 104: 503-513.
80. Takeda Y, Caudell P, Grady G, Wang G, Suwa A, Sharp GC et al. (1999). Human RNA helicase A is a lupus autoantigen that is cleaved during apoptosis. J Immunol 163: 6269-6274.
81. Tange TO, Nott A, Moore MJ. (2004). The ever-increasing complexities of the exon junction complex. Curr Opin Cell Biol 16: 279-284.
82. Thebault S, Basbous J, Hivin P, Devaux C, Mesnard JM. (2004). HBZ interacts with JunD and stimulates its transcriptional activity. FEBS Lett 562: 165-170.
83. Thepot D, Weitzman JB, Barra J, Segretain D, Stinnakre MG, Babinet C et al. (2000). Targeted disruption of the murine junD gene results in multiple defects in male reproductive function. Development 127: 143-153.
84. Treier M, Staszewski LM, Bohmann D. (1994). Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78: 787-798.
85. Troen G, Nygaard V, Jenssen TK, Ikonomou IM, Tierens A, Matutes E et al. (2004). Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma. J Mol Diagn 6: 297-307.
86. Tsuji Y. (2005). JunD activates transcription of the human ferritin H gene through an antioxidant response element during oxidative stress. Oncogene 24: 7567-7578.
87. Uria JA, Jimenez MG, Balbin M, Freije JM, Lopez-Otin C. (1998). Differential effects of transforming growth factor-beta on the expression of collagenase-1 and collagenase-3 in human fibroblasts. J Biol Chem 273: 9769-9777.
88. Weitzman JB, Fiette L, Matsuo K, Yaniv M. (2000). JunD protects cells from p53-dependent senescence and apoptosis. Mol Cell 6: 1109-1119.
89. Wiegand HL, Lu S, Cullen BR. (2003). Exon junction complexes mediate the enhancing effect of splicing on mRNA expression. Proc Natl Acad Sci USA 100: 11327-11332.
90. Willingham AT, Gingeras TR. (2006). TUF love for 'junk' DNA. Cell 125: 1215-1220.
91. Xiao L, Rao JN, Zou T, Liu L, Marasa BS, Chen J et al. (2007). Induced JunD in intestinal epithelial cells represses CDK4 transcription through its proximal promoter region following polyamine depletion. Biochem J 403: 573-581.
92. Yang SH, Sharrocks AD. (2004). SUMO promotes HDAC-mediated transcriptional repression. Mol Cell 13: 611-617.
93. Yazgan O, Pfarr CM. (2001). Differential binding of the Menin tumor suppressor protein to JunD isoforms. Cancer Res 61: 916-920.
94. Yazgan O, Pfarr CM. (2002). Regulation of two JunD isoforms by Jun N-terminal kinases. J Biol Chem 277: 29710-29718.
95. Yilmaz A, Bolinger C, Boris-Lawrie K. (2006). Retrovirus translation initiation: Issues and hypotheses derived from study of HIV-1. Curr HIV Res 4: 131-139.
96. Zenz R, Wagner EF. (2006). Jun signalling in the epidermis: from developmental defects to psoriasis and skin tumors. Int J Biochem Cell Biol 38: 1043-1049.
97. Zerbini LF, Wang Y, Cho JY, Libermann TA. (2003). Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 63: 2206-2215.
98. Zhang S, Grosse F. (2004). Multiple functions of nuclear DNA helicase II (RNA helicase A) in nucleic acid metabolism. Acta Biochim Biophys Sin (Shanghai) 36: 177-183.
99. Zhang Y, Xiong Y, Yarbrough WG. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734.
100. Zhou H, Gao J, Lu ZY, Lu L, Dai W, Xu M. (2007). Role of c-Fos/JunD in protecting stress-induced cell death. Cell Prolif 40: 431-444.